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Abstract
Background: Despite changes in the treatment paradigm towards non-interferon-based therapies, interferon-based
treatments are still used in some geographical regions for treating patients with hepatitis C virus (HCV) infection.
Use of eltrombopag with interferon-based treatment for patients with thrombocytopenia and HCV was assessed in
two similarly designed phase 3 trials (Eltrombopag to Initiate and Maintain Interferon Antiviral Treatment to
Benefit Subjects With Hepatitis C-Related Liver Disease [ENABLE-1 and ENABLE-2]). These trials also aimed to
determine whether response to antiviral therapy (e.g., sustained virologic response [SVR]) is associated with
changes in health-related quality of life (HRQoL). This pooled, post-hoc analysis aimed to (1) determine whether or not
specific aspects of clinical response to treatment (i.e., achieving SVR) are associated with a significant change
in HRQoL, and (2) to determine the magnitude and direction of the association between important changes
in HRQoL, clinical response to interferon-based therapy (e.g., SVR) and treatment (eltrombopag or placebo),
and patient and disease attributes.
Methods: The Short-Form 36 Health Survey version 2 and Chronic Liver Disease Questionnaire–Hepatitis C Virus
version were administered at various time points during the studies. Results from both trials were pooled for the
analyses. Logistic regression analysis was used to assess the influence of 5 clinical factors (SVR, early virologic response
[EVR], genotype [2/3 vs. non-2/3], treatment [eltrombopag or placebo], and cumulative interferon dose), plus other
factors including ethnicity, model of end-stage liver disease score, and platelets as predictors of meaningful changes
in HRQoL.
Results: Between antiviral therapy baseline and the end of the 24-week post-treatment follow-up, declines in HRQoL
were smaller in eltrombopag-treated patients than in placebo-treated patients, but the differences were not statistically
significant. Mean changes among patients achieving SVR and EVR were small in comparison to thresholds of minimally
important changes. Logistic models did not confirm the strength of the 5 clinical factors as predictors of meaningful
changes in HRQoL during antiviral therapy, with the exception of the interaction between SVR and EVR (P = 0.0009).
Asian ethnicity had a consistent effect on HRQoL, with East Asian patients being more likely to experience deterioration
in HRQoL compared with white and/or other non-East Asian patients.
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Conclusions: While on active antiviral therapy, declines in HRQoL were not statistically different for eltrombopag-
treated patients versus placebo-treated patients, suggesting that eltrombopag neither worsened HRQoL nor mitigated
the effects of antiviral therapy on HRQoL.
Keywords: Eltrombopag, Hepatitis C virus, HRQoL, Peginterferon alfa-2a, Ribavirin, Virologic response
Background
Thrombocytopenia is a frequent complication in patients
with chronic hepatitis C virus (HCV) infection and
correlates with liver disease severity [1]. It is more severe
in patients with advanced disease undergoing interferon
(IFN)-based antiviral therapy (AVT) and can be attrib-
uted to antiviral infection-induced liver cirrhosis and the
inhibitory effects of IFN on thrombopoietin-induced
development of megakaryocytic progenitor cells [1–4].
Chronic HCV infection is associated with reduced
health-related quality of life (HRQoL), having a greater
impact in patients with more severe liver disease [5].
Although decreased HRQoL was documented during
the course of therapy with pegylated IFN (PEG-IFN)
and ribavirin, multiple studies showed that HRQoL is
restored to pre-AVT levels following stopping of IFN-
based AVT after achieving a sustained virologic re-
sponse (SVR) [6–11].
Eltrombopag (Promacta, GlaxoSmithKline, Research Tri-
angle Park, NC, USA) is an oral, nonpeptide thrombopoie-
tin receptor agonist approved for the treatment of
thrombocytopenia in patients with chronic HCV to allow
the initiation and maintenance of IFN-based AVT based
on the ENABLE-1 and ENABLE-2 trials (ClinicalTrials.gov
identifiers: NCT00516321 and NCT00529568, respectively)
[12]. The ENABLE trials included a difficult-to-treat group
of thrombocytopenic HCV-infected patients otherwise in-
eligible for IFN-based AVT based on their platelet counts.
The pivotal ENABLE trials not only established the
efficacy and safety of eltrombopag in patients with HCV-
associated thrombocytopenia, but also assessed HRQoL
through the Short-Form 36 Health Survey version 2
(SF-36v2) and Chronic Liver Disease Questionnaire–
HCV version (CLDQ-HCV) [13–15]. Although effective,
therapy with IFN and ribavirin has side effects such as flu-
like symptoms, anemia, and emotional changes [16, 17]
that affect HRQoL [5, 18]. Based on published reports
documenting the negative effects of IFN-based AVT on
HRQoL [19, 20], HRQoL in patients in the ENABLE
studies was expected to decline during the 24–48 weeks
of IFN therapy due to the cumulative nature of the effects
of IFN, and to return to baseline levels at the 24-weeks
post-treatment follow-up visit [19]. Several reports indi-
cate that patients who achieve SVR have improved
HRQoL compared to patients who do not achieve SVR
[7–11, 21, 22]. This pooled, post-hoc analysis aimed to
(1) determine whether or not specific aspects of
clinical response to treatment, such as achieving a
SVR, are associated with a significant change in
HRQL, and (2) to determine the magnitude and
direction of the association between important
changes in HRQoL, clinical response to IFN-based
AVT (e.g., SVR) and treatment (eltrombopag or
placebo), and patient and disease attributes.
Methods
Study design
The similarly designed ENABLE studies (Fig. 1) differed
in the PEG-IFN used with oral ribavirin (ENABLE-1,
PEG-2a; ENABLE-2, PEG-2b) and the platelet thresholds
for initiating AVT (ENABLE-1, 90 × 109/L; ENABLE-2,
100 × 109/L) [12]. The protocols for both studies were
reviewed and approved by the applicable ethics com-
mittee or institutional review boards at each center,
in accordance with the International Conference on
Harmonisation guidelines, applicable country-specific
requirements, and the ethical principles of the 2008
Declaration of Helsinki. Written informed consent
was obtained from all participants. Each study in-
cluded a 2–9-week open-label phase during which
the eltrombopag dose was titrated based on platelet
response (Fig. 1). Patients not achieving platelet
thresholds despite receiving eltrombopag 100 mg/day
for 3 weeks entered the follow-up period. End of
treatment was defined as the end of the planned
AVT duration (24 weeks for genotypes 2/3, 48 weeks
for non-genotypes 2/3, or withdrawal, whichever
occurred first).
The American Association for the Study of Liver
Diseases guidelines for stopping and futility were applied
to PEG-IFN treatment [23]. Patients were stratified by
HCV genotype (2/3 vs. non-2/3), baseline platelet counts
(<50 × 109/L vs. ≥50 × 109/L), and HCV viral load
(<800,000 vs. ≥800,000 IU/mL) at baseline [12]. All indi-
viduals involved in the study were blinded to treatment
assignments.
PEG-IFN dose modifications were determined by local
package instructions. The eltrombopag dose was
reduced if the platelet count was >200 × 109/L, and
treatment interrupted and the dose reduced if the plate-
let count exceeded 400 × 109/L.
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SVR was defined as continued non-detectable HCV
RNA 24 weeks after completion of AVT (generally 48 or
72 weeks following initiation of AVT for genotypes 2/3
or at 72 weeks for non-genotype 2/3). EVR was defined
as a reduction in HCV RNA (≥2 log10 drop or undetect-
able RNA) after 12 weeks of antiviral treatment. HRQoL
was assessed at five time points during the ENABLE
trials: baseline prior to receiving eltrombopag only
(Eltrombopag Alone), at the time of randomization prior
to INF-based therapy, Week 12, end of IFN-based ther-
apy, and at the 24-week follow up visit (Fig. 2). However,
only three HRQoL assessments are considered in this
analysis; those done at the time of randomization, at the
end of IFN-based therapy, and at the 24-week follow up
visit, which corresponded to the final assessment of
SVR. HRQoL was assessed prior to any interaction with
physicians or staff, or release of information regarding
viral load.
Measures of HRQoL
This study used 2 patient-reported outcome instru-
ments: SF-36v2 and CLDQ-HCV [6, 13].
Acute recall form of the SF-36v2
The SF-36 is a 36-item survey of self-reported functional
health and well-being reported over 7 days [13]. Re-
sponses to 35 of the 36 items enable computation of a
profile of functional health and well-being that consists
of 8 subscales or HRQoL domains: physical functioning,
role limitations due to physical health (role-physical),
bodily pain, general health perceptions, vitality, social
functioning, role limitations due to emotional problems
(role-emotional), and mental health. Physical and
mental health component summary (PCS and MCS,
respectively) scores are then computed using the 8
subscales, to provide a broader metric of physical and
mental HRQoL. The technique of norm-based scoring
(NBS) is used to calculate the subscales and compos-
ite scores; this technique transforms or standardizes
scale and component scores using the means and
standard deviations (SDs) from a general US
population normative sample (QualityMetric 2009
PRO Norming Study, QualityMetric, Lincoln, RI,
USA; Additional file 1), drawn from a national prob-
ability sample of US non-institutionalized adults
Fig. 1 Design of the ENABLE trials* and timing of the SF-36v2 and CLDQ-HCV (HRQoL) assessments. *Each study included an open-label initiation phase,
with patients receiving eltrombopag 25–100 mg for up to 9 weeks, with dose escalations being guided by platelet response. Patients whose platelet
counts increased to a prespecified threshold to initiate AVT (ENABLE-1, 90 × 109/L; ENABLE-2, 100 × 109/L) were randomized 2:1 to receive either the same
dose of eltrombopag they had received during the initiation phase or matching placebo. Hepatocellular carcinoma and portal vein thrombosis were
assessed between screening and baseline and every 6 months thereafter through Doppler ultrasound of the abdomen. During the AVT phase, patients in
ENABLE-1 were administered PEG-2a at 180 μg/week with RBV at 800 mg/day if they were infected with genotypes 2/3. If they were infected
with genotypes other than 2/3, RBV doses were determined by body weight, with patients weighing <75 kg being given 1000 mg/day and
patients weighing ≥75 kg being given 1200 mg/day. The weekly PEG-2b dose in ENABLE-2 was 1.5 μg/kg, while RBV doses were 800 mg/day,
1000 mg/day, 1200 mg/day, or 1400 mg/day based on body weights of ≤65 kg, 65–80 kg, 81–105 kg, or >105 kg, respectively. †Twenty-four
weeks for genotypes 2/3 and 48 weeks for other genotypes of hepatitis C virus. ‡PEG-2a in ENABLE-1 and PEG-2b in ENABLE-2. AVT, antiviral
therapy; CLDQ-HCV, Chronic Liver Disease Questionnaire–Hepatitis C Virus version; HRQoL, health-related quality of life; PEG, pegylated interferon; RBV,
ribavirin; SF-36v2, Short-Form 36 Health Survey version 2; SVR, sustained virologic response
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(KnowledgePanel, GfK Custom Research North America,
New York, NY, USA). The NBS in the general US popula-
tion is set to a mean ± SD of 50 ± 10 (i.e., T scores). Conse-
quently, all scores <50 can be interpreted as being below,
and scores >50 can be interpreted as being above, the
general US population norm. All scales and component
scores with NBS are scored on a common metric and
facilitate meaningful comparisons. For more information
on the calculation of NBS scale scores, see the Additional
file 1 [13, 24].
Scores for the SF-36v2 PCS and MCS were derived
according to the algorithm described by Farivar and
colleagues [24] (Additional file 1). This algorithm differs
from the original SF-36v2 with regard to summary score
calculation in that it uses a correlated (oblique) physical
and mental health factor model in lieu of the uncorre-
lated (orthogonal) factor solution used in the original
SF-36v2.
The SF-36v2 has been used previously among pa-
tients with HCV and advanced fibrosis, had good
measurement properties, and was responsive to
change over time within patient populations without
cirrhosis and with less severe liver disease [10, 25].
The literature suggests the SF-36v2 is capable of dif-
ferentiating between patients with chronic HCV who
do and do not achieve SVR. Those achieving SVR
report better HRQoL, especially on role-physical and
general health domains [7–11, 21, 22]. Generally,
chronic HCV infection has a pronounced impact on
the vitality, general health, physical function, and
social function dimensions of the SF-36 [5, 9].
CLDQ-HCV
The CLDQ-HCV, which is based on the CLDQ [6, 15],
is a 29-item patient self-reported questionnaire devel-
oped to measure HRQoL among patients with chronic
liver disease and HCV. Approximately one-half of the
questions in the CLDQ and the CLDQ-HCV are com-
mon. The remaining questions focus on symptoms and
issues unique to HCV. The CLDQ-HCV was designed
with a 2-week recall period, and items fall into 4
domains: activity/energy, emotion, systemic symptoms,
and worry. Each item uses 7-point Likert scales ranging
from 1 (all the time) to 7 (none of the time).
Responses on the CLDQ-HCV were coded into
domain scores according to the algorithms designed
by the developers; greater scores indicate better
HRQoL. This permits decrements in HRQoL from
baseline to be captured as negative values, while im-
proved status is captured as positive values. Domain
scores were calculated by averaging the responses
within each domain, with the responses ranging from
1 to 7. An overall score was calculated by averaging
scores across the 4 domains.
Statistical analysis
Differences between groups for normally distributed vari-
ables were evaluated and tested for statistical significance
using analysis of variance (ANOVA) or analysis of covari-
ance (ANCOVA) models. When comparing means among
three or more groups, if significant differences were ob-
served from omnibus ANOVA or ANCOVA models, post-
Fig. 2 Mean values over time for SF-36v2 and CLDQ-HCV. CLDQ-HCV, Chronic Liver Disease Questionnaire–Hepatitis C Virus version; IFN, interferon;
MCS, mental component summary; PCS, physical component summary; SF-36v2, Short-Form 36 Health Survey version 2
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hoc pair-wise comparison of means were computed using
Tukey’s test to control for alpha inflation. The Chi-Square
and Fisher’s exact tests were used to assess statistical signifi-
cance related to contingency tables.
Differences between groups were interpreted using
Cohen’s d [26]. For analyses of change scores, Cohen’s d
was calculated as the ratio of the difference in mean
change scores between the eltrombopag and placebo
groups versus the pooled standard deviation of the
changes scores.
Models of clinical factors associated with important
changes in HRQoL
The association between important changes in HRQoL
and 5 clinical factors (SVR, EVR, genotype [2/3 vs. non-
2/3], treatment [eltrombopag vs. placebo], and cumula-
tive dose of IFN) was evaluated using logistic regression
models with the following independent variables: the 5
clinical factors, age (<40 vs. ≥40 years), sex, ethnicity
(East Asian, other Asian, white, and other), baseline
Model for End-Stage Liver Disease (MELD) score (<10
vs. ≥10), baseline platelet count (<50 × 109/L vs. ≥50 ×
109/L), and interaction terms between SVR and EVR,
treatment and EVR, and genotype and cumulative IFN
dose. Two dependent variables were evaluated for each
HRQoL scale (8 subscales and 2 summary measures of
the SF-36v2 [PCS and MCS] and 4 subscales and overall
score of the CLDQ-HCV). “Drop in HRQoL score” was
defined as a drop in HRQoL greater in magnitude than
the minimally important change (MIC) during active
AVT (end of treatment – AVT baseline). “Return to
baseline score” was defined as a 24-week post-treatment
follow-up HRQoL score within the MIC of the AVT
baseline.
The MIC for the CLDQ-HCV was defined as one-half
of the SD of the AVT baseline score [27]: overall
HRQoL = 0.6; energy/activity = 4.0; emotion = 4.8; sys-
temic = 3.8; and worry = 5.4. For SF-36v2 scores derived
using NBS, the recommended MIC values were used to
evaluate important changes: 3.4, 4.6, 4.3, 3.4, 6.2, 7.2,
6.2, 6.9, 4.5, and 6.2, for PCS, MCS, physical functioning,
role-physical, bodily pain, general health perceptions, so-
cial functioning, role-emotional, and mental health
scores, respectively [13]. Each patient in the ENABLE
pooled sample was classified as experiencing a meaning-
ful change if the difference between his or her baseline
and post-baseline scores was greater in absolute value
than the MIC.
The predictive powers of both SVR and EVR were
modeled because both characterize response to therapy.
Other considerations that underlie the model include
that duration of AVT depends upon genotype [28] and
that exposure for 80 % of the planned time and at 80 %
of the planned dose of IFN is associated with the great-
est likelihood of sustained viral response [29].
The model used to estimate the log odds of each
HRQoL outcome is as follows:
log
P HRQoL outcome ¼ 1½ 





¼ αþ β1SVRþ β2EVRþ β3Gen2; 3þ β4Eltrombopag
þβ5IFN þ β6 Age < 40ð Þ þ β7Maleþ β8 East Asianð Þ
þ β9 Other Asianð Þ þ β10MELD < 10ð Þ þ β11 Plat < 50ð Þ
þβ12EVR  SVRþ β13Eltrombopag  IFN
þβ14Gen2; 3  IFN
Model assumptions were evaluated for lack of fit and
evidence of multicollinearity. The assumption of linearity
between continuous variables and the logit of the out-
come was examined using the Hosmer-Lemeshow test
[30]. Excessive collinearity or other indications of model
misfit or violation of model assumptions led to modifi-
cations to the proposed model specifications.
Hierarchy of significance testing for HRQoL scales
The PCS and MCS of the SF36v2 and the overall
HRQoL as derived from the CLDQ-HCV were modeled
first, followed by the subscales representing challenges
to physical health and functioning. The subscales or
domains capturing mental and emotional health were
modeled last. Table 1 shows the hierarchical order for
testing of the null hypotheses.
Results are presented as odds ratios (ORs; with confi-
dence intervals) for each HRQoL outcome. Model
parameters provide the OR of the HRQoL event (drop dur-
ing treatment or return to baseline level at the 24-week
post-treatment follow-up assessment) for the groups repre-
sented by that factor (e.g., patients who achieved SVR vs.
those who did not). For the cumulative IFN dose—a con-
tinuous variable—the interpretation of the OR refers to the
effect of a 1-point difference in the cumulative IFN dose.
Multiplicity adjustments and hypotheses tested
Two families of hypotheses (Specifications A and B) were
defined as follows: the odds of restoring HRQoL at the
Week 24 follow-up visit (Specification A) or the odds of a
drop in HRQoL greater than the MIC during active AVT
(Specification B), where HRQoL is measured as scores on
the SF-36v2 and CLDQ-HCV. Specification A tests
whether the odds of restoring HRQoL at the 24-week
post-treatment follow-up visit are significantly greater for
patients with one of the 5 clinical factor characteristics
(e.g., SVR) compared to patients without that characteris-
tic (e.g., non-SVR). Specification B tests whether the odds
of a drop in HRQoL greater than the MIC during active
AVT are significantly greater among patients with one of
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the 5 clinical factor characteristics (e.g., SVR) compared to
patients without that characteristic (e.g., non-SVR).
Fifteen tests were conducted for each specification,
with 1 test conducted per HRQoL domain or summary
score defined previously. Adjustment for multiplicity
was explored. Model specifications were fitted for the
purpose of answering the research questions and reflect
underlying data structure assumptions, goodness-of-fit
statistics, and embedded adjustments for multiple tests.
The study also examined logistic regression models (data
not shown), which permitted the exclusion of particular
clinical variables and/or interactions among the variables
(not reported) reflecting a priori concerns of multicollinear-
ity among clinical predictors, particularly the relationship
between SVR and EVR, as well as a posteriori consider-
ations. Type 3 analysis of effects was used to determine
P values for each variable included in the model using
SAS/STAT(R) version 9.22 (SAS, Cary, NC, USA).
Results
Baseline demographic and clinical characteristics of the
combined group of patients from the ENABLE-1 and
ENABLE-2 trials (n = 1441) are shown in Table 2. At
baseline, mean SF-36v2 acute PCS and MCS scores (sub-
mission scoring) of the pooled patient population were
47.1 and 47.0, respectively, while respective median PCS
and MCS scores were 48.6 and 48.3. The mean (median)
overall CLDQ-HCV scores of the pooled population
were 4.9 (5.0). Mean (median) scores on the individual
components of the CLDQ-HCV were: activity, 29.7
(31.0); emotion, 44.3 (46.0); systemic symptoms, 29.1
(30.0); and worry, 38.9 (40.0).
Changes in HRQoL scores across treatment and viral
response groups
Changes in mean scores for the SF-36v2 and CLDQ-
HCV over the trial period are shown in Fig. 2. The mean
change in scores between Week 24 and AVT baseline
ranged between −2 and −3, indicating that SF-36v2 and
CLDQ-HCV scores were lower at Week 24 than at base-
line. There were small differences between the eltrombo-
pag and placebo groups. The small group differences
between Week 24 and AVT baseline, and the lack of
statistical significance related to treatment in the EN-
ABLE studies, may be partially because the number of
observations was too small to make a robust estimate.
Mean changes in HRQoL scores between the end of
treatment (24 or 48 weeks, depending on the genotype)
and baseline are shown in Table 3 [24]. Achievement of
either EVR or SVR did not explain the changes in
HRQoL. There was a slight decline in SF-36v2 and
CLDQ-HCV scores between AVT baseline and 24 weeks
post-treatment among patients who did and did not
achieve EVR (data not shown).
The association between EVR at 12 weeks post-AVT
baseline and HRQoL change scores was weak, with SF-
36v2 mean change scores that ranged from −6.5 to −3.9
among patients who did not achieve EVR and from −6.4
to −2.7 among those who achieved EVR. For the 5 CLDQ-
HCV scales, mean change scores ranged from −5.8 to −0.7
among patients who did not achieve EVR and from −5.5
to −0.5 for those who achieved EVR at 12 weeks.
Declines in SF-36v2 and CLDQ-HCV scores among
those who achieved SVR (SVR group) were systematic-
ally smaller compared with patients who did not achieve
SVR (non-SVR group). These group differences were
Table 1 Hierarchical order for testing of the null hypotheses
SF-36v2 CLDQ-HCV
Aggregate summary scores
Physical functioning (PCS scores) Overall HRQoL (average of the 4 domain scores of the CLDQ-HCV)
Mental well-being (MCS scores)
Physical health and functioning domain scores




Mental and emotional health scores
Mental health (SF-36v2 subscale) Emotion
General health (SF-36v2 subscale) Worry
Role-emotional (SF-36v2 subscale)
Social functioning (SF-36v2 subscale)
CLDQ-HCV chronic liver disease questionnaire–hepatitis C virus version, HRQoL health-related quality of life, MCS, mental component summary, PCS, physical
component summary, SF-36v2 short-form 36 health survey version 2
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above the 0.2 threshold value that indicates a small group
effect for all but 2 of the SF-36v2 scales: social functioning
and role-emotional. The largest effect size (Cohen’s d =
0.56) was observed for the general health scale. For this
scale, the mean change corresponded to an actual increase
of 1.7 points in the SVR group and a decline of −3 points
in the non-SVR group. Mean change scores experienced by
both SVR and non-SVR groups were smaller than the rec-
ommended MIC of 7.2 for the general health scale. All SF-
36v2 mean change scores were smaller than MIC estimates.
Similarly, although effects for the CLDQ-HCV were >0.3
for all scales, the mean change scores were smaller than the
MIC values in all cases.
Logistic regression analyses: clinical factors as predictors
of meaningful changes in HRQoL
Results of the logistic regression analysis during AVT
(from AVT baseline to end of treatment) showed no OR
differences in patients’ decrease in overall CLDQ-HCV
score, relative to the MIC, for any of the 5 clinical fac-
tors or the specified interactions (Fig. 3a, goodness of fit
is shown in Additional file 2). However, these results did
show an ethnicity effect (P = 0.0025): East Asians were
significantly more likely to report a meaningful drop in
overall CLDQ-HCV score versus non-East Asians (OR
2.09 [95 % CI: 1.30, 3.34]), while non-East Asians were
significantly less likely to report such a drop versus
whites/other ethnicities (OR 0.56 [95 % CI: 0.39, 0.80]).
Although model details suggest a good fit of the model
to the data, the very small R2 value (0.02) and relatively
small AUC (0.56) indicate that the group of variables in-
cluded in the model is a poor predictor of whether a pa-
tient’s CLDQ-HCV score drops by a meaningful amount
from study baseline to endpoint.
Analysis of return to AVT baseline and restoration of
baseline HRQoL after completing 24 weeks of treatment
are shown in Fig. 3b. None of the 5 clinical factors or
viral response interaction terms was found to influence
the ORs of patients’ return to their AVT baseline overall
CLDQ-HCV score at the 24-week post-treatment follow-
up. These results also showed an ethnicity effect
(P = 0.0207): patients of East Asian ethnicity were signifi-
cantly more likely to demonstrate a return to their
baseline overall CLDQ-HCV score at the 24-week post-
treatment follow-up versus non-East Asians (OR 1.89
[95 % CI: 1.19, 3.02]) or whites/other ethnicities (OR
1.54 [95 % CI: 1.07, 2.22]). Significant differences were
also found regarding the MELD score (P = 0.02): patients
with a MELD score <10 were significantly more likely to
demonstrate a return to their baseline overall CLDQ-
HCV score versus those with a score ≥10 at the 24-week
post-treatment follow-up (OR 1.30 [95 % CI: 1.04, 1.62]).
Although the model details support a good fit to the
data, the very small R2 value (0.02) and relatively small
area under the curve (AUC; 0.58) indicate that the group
of variables included in the model is a poor predictor of
whether a patient returns to his or her baseline overall
CLDQ-HCV score.
Among the non-SVR group, a statistically significant
decrease in the ORs of a meaningful drop in PCS
scores relative to the MIC, from AVT baseline to the
end of AVT, was found for patients who did not
achieve EVR versus those who did (OR 0.65 [95 %
CI: 0.49, 0.85]) (Fig. 4a). No significant differences in
the ORs of demonstrating a meaningful drop in PCS
scores from AVT baseline to the end of AVT were
found between East Asians and other ethnicities (OR
0.85 [95 % CI: 0.59, 1.23]), although an overall race
effect was demonstrated (P = 0.0064) due to non-East
Asians being significantly less likely to experience
such a drop versus whites/other ethnicities (OR 0.56
[95 % CI: 0.39, 0.80]).
Table 2 Baseline demographic and clinical characteristics






Baseline platelet count (×109/L)
Mean (SD) 56.9 (13.4)
Median 59.5




≥ 40 years 1338 (92.9)
< 40 years 103 (7.2)
Bridging fibrosis/cirrhosis
Patients with measurements, n 1268
n (%) 1143 (90.1)
Ethnicity, n (%)
White/Other 1109 (77.0)
Other Asians 186 (12.9)
East Asians 146 (10.1)
Actual HCV genotype, n (%)
Non-2/3 or missing 995 (69.0)
2/3 446 (31.0)
Body mass index, n (%)
< 30 kg/m2 1028 (71.3)
≥ 30 kg/m2 406 (28.2)
Missing 7 (0.5)
Depression in past medical history 17 (1.2)
AVT, antiviral therapy, HCV hepatitis C virus, SD standard deviation
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Fig. 3 Odds ratios of changes in CLDQ-HCV scores at various time points. Odds of (a) a drop in CLDQ-HCV scores greater than the MIC at the end of
AVT treatment and (b) a return to baseline levels in overall CLDQ-HCV score. AVT, antiviral therapy; CD, cumulative dose; CLDQ-HCV, Chronic Liver
Disease Questionnaire–Hepatitis C Virus version; EVR, early virologic response; IFN, interferon; MELD, Model for End-Stage Liver Disease; MIC, minimally
important change; SVR, sustained virologic response
Table 3 Drop in SF-36 and CLDQ-HCV HRQoL scores from antiviral baseline to end of ATV treatment, and at the 24-week
post-treatment follow-up by treatment group
Drop in ATV BL to End of Treatment Mean (95 % CI) Drop in ATV BL to 24-week FU Mean (95 % CI)
PBO EPAG Cohen’s d PBO EPAG Cohen’s d
SF-36v2 acute
Physical functioning −5.2 (−6.1, −4.4) 4.8 (−5.4, −4.2) 0.05 −2.2 (−3.1, −1.4) −1.6 (−2.2, −1.0) 0.08
Role-physical −4.7 (−5.7, −3.8) −5.5 (−6.2, −4.8) −0.08 2.4 (−3.3, −1.4) −2.2 (−2.9, −1.6) 0.02
Bodily pain −4.6 (−5.6, −3.7) −4.8 (−5.5, −4.1) −0.02 2.3 (−3.4, −1.3) −1.7 (−2.4, −1.0) 0.06
General health −3.8 (−4.5, −3.0) −2.9 (−3.4, −2.3) 0.11 2.3 (−3.1, −1.4) −1.8 (−2.4, −1.2) 0.06
Vitality −6.0 (−7.0, −5.1) −6.1 (−6.7, −5.4) −0.00 −2.1 (−3.0, −1.2) −1.4 (−2.1, −0.8) 0.07
Social functioning −5.3 (−6.3, −4.3) −6.5 (−7.3, −5.8) −0.12 2.5 (−3.5, −1.6), −2.2 (−2.9, −1.5) −0.12
Role-emotional −5.3 (−6.5, −4.0) −6.8 (−7.7, −5.8) −0.11 −3.1 (−4.2, −2.0) −2.8 (−3.7, −1.9) 0.03
Mental health −5.8 (−6.7, −4.9) −5.3 (−6.0, −4.6) 0.05 −2.1 (−3.0, −1.1) −1.7 (−2.4, −1.1) 0.07
PCSa −5.8 (−6.6, −5.0) −6.2 (−6.8, −5.6) −0.05 −2.8 (−3.6, −1.9) −2.3 (−2.8, −1.7) 0.03
MCSa −6.3 (−7.2, −5.4) −6.4 (−7.1, −5.8) −0.02 −2.6 (−3.5, −1.7) −2.1 (−2.7, −1.5) 0.06
CLDQ-HCV
Overall −0.6 (−0.7, −0.5) −0.6 (−0.6, −0.5) 0.02 −0.3 (−0.4, −0.2) −0.2 (−0.3, −0.2) 0.06
Activity −5.6 (−6.3, −4.8) −5.6 (−6.2, −5.1) −0.01 −1.9 (−2.7, −1.2) −1.8 (−2.3, −1.3) 0.02
Emotion −4.8 (−5.7, −3.8) −4.5 (−5.1, −3.9) 0.03 −1.9 (−2.8, −1.0) −1.8 (−2.4, −1.1) 0.02
Systemic symptoms −4.0 (−4.6, −3.3) −4.0 (−4.4, −3.5) −0.00 −2.3 (−3.0, −1.6) −1.7 (−2.2, −1.3) 0.09
Worry −2.5 (−3.4, −1.6) −1.8 (−2.4, −1.2) 0.07 −1.7 (−2.7, −0.7) −0.9 (−1.6, −0.2) 0.08
CI confidence interval, CLDQ-HCV chronic liver disease questionnaire–hepatitis C virus version, MCS mental component summary, PCS physical component
summary, SF-36v2 short-form 36 health survey version 2
aScored as a correlated physical and mental health factor model [24]
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At the 24-week post-treatment follow-up visit post-
AVT, no differences were found in the ORs of patients’
return to their baseline SF-36v2 PCS score across any of
the 5 clinical factors or the specified interactions (Fig. 4b;
goodness of fit is shown in Additional file 2). The results
show an ethnicity effect (P = 0.0017): East Asians were
significantly more likely to demonstrate a return to base-
line PCS score at the 24-week post-treatment follow-up
versus non-East Asians (OR 2.41 [95 % CI: 1.48, 3.92])
or whites/other ethnicities (OR 1.64 [95 % CI: 1.13,
2.37]), while non-East Asians were significantly less
likely to demonstrate a return versus whites/other
ethnicities (OR 0.68 [95 % CI: 0.46, 0.99]). Significant
differences were also found regarding the MELD score
(P = 0.0009): patients with a MELD score <10 were sig-
nificantly more likely to demonstrate a return to their
baseline PCS score at the 24-week post-treatment
follow-up versus those with a score ≥10 (OR 1.48 [95 %
CI: 1.18, 1.87]). Again, model details suggest a good fit
of the model to the data (Additional file 2); however, the
very small R2 value (0.02) and relatively small AUC
(0.58) indicate this group of variables is a poor predictor
of whether a patient returns to their baseline PCS score.
Differences in the ORs of return to baseline SF-36v2
PCS (correlated physical and mental health factor
model) scores at the 24-week post-treatment follow-up
across some of the 5 clinical factors were also found
(Fig. 4c). These differences between AVT baseline and
the 24-week post-treatment follow-up included: statisti-
cally significantly greater odds for a return to baseline in
PCS (correlated physical and mental health factor
model) scores for patients who did not achieve EVR ver-
sus those who did (OR 1.36 [95 % CI: 1.01, 1.82]); statis-
tically significantly larger odds of experiencing a return
to AVT baseline for patients with a non-2/3 genotype
(OR 1.37 [95 % CI: 1.02, 1.84]); East Asians were
Fig. 4 Odds ratios of changes in SF-36v2 PCS and MCS scores at various time points. Odds of (a) a drop in SF-36v2 PCS scores greater than the MIC at
the end of AVT treatment; (b) a return to baseline levels in SF-36v2 PCS scores; (c) a return to baseline levels in SF-36v2 PCS (submission scoring) scores;
(d) a drop in SF-36v2 MCS scores greater than the MIC at the end of AVT treatment; (e) a return to baseline levels in SF-36v2 MCS scores; and (f) a return
to baseline levels in SF-36v2 MCS (submission scoring) scores. AVT, antiviral therapy; CD, cumulative dose; EVR, early virologic response;
IFN, interferon; MELD, Model for End-Stage Liver Disease; MIC, minimally important change; SF-36v2, Short-Form 36 Health Survey version 2; SVR,
sustained virologic response
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significantly more likely to demonstrate a return to their
baseline PCS (correlated physical and mental health fac-
tor model) score versus non-East Asians (OR 1.936
[95 % CI: 1.18, 3.18]), and non-East Asians were also sig-
nificantly less likely to demonstrate a return versus
whites/other ethnicities (OR 0.63 [95 % CI: 0.43, 0.92]);
and a significantly increased odds of patients with a
MELD score <10 demonstrating a return to their base-
line PCS (correlated physical and mental health factor
model) score (OR 1.49 [95 % CI: 1.17, 1.89]).
Increased odds of a meaningful drop in MCS scores
from AVT baseline to the end of AVT relative to the MIC
were related to race (P = 0.0020), with East Asians more
likely to experience such a drop relative to non-East
Asians (OR 1.81 [95 % CI: 1.13, 2.90]); non-East Asians
were also significantly less likely to demonstrate such a
drop versus whites/other ethnicities (OR 0.525 [95 % CI:
0.37, 0.75]). Among the non-SVR group, patients who did
not achieve EVR had a statistically significant decrease in
the ORs of a drop in their MCS score that exceeded the
MIC from baseline to the end of AVT versus patients who
achieved EVR (OR 0.663 [95 % CI: 0.50, 0.87]) (Fig. 4d).
No differences in the ORs of patients’ return to base-
line SF-36v2 MCS scores at the 24-week post-treatment
follow-up were found across any of the 5 clinical factors
or the specified interactions (Fig. 4e). Results show an
ethnicity effect (P = 0.0072): East Asians were signifi-
cantly more likely to demonstrate a return to their base-
line MCS score at the 24-week post-treatment follow-up
visit than were non-East Asians (OR 1.91 [95 % CI: 1.17,
3.14]), while non-East Asians were significantly less
likely to demonstrate a return than were whites/other
ethnicities (OR 0.550 [95 % CI: 0.37, 0.81]). Significant
differences (P = 0.0183) were also found regarding the
MELD score: patients with a MELD score <10 were sig-
nificantly more likely to demonstrate a return to their
baseline MCS score at the 24-week post-treatment
follow-up visit versus patients with a MELD score ≥10
(OR 1.32 [95 % CI: 1.05, 1.66]).
No differences in the ORs of patients’ return to base-
line SF-36v2 MCS (correlated physical and mental health
factor model) scores at the 24-week post-treatment
follow-up were found across any of the 5 clinical factors
for the MCS scored using the alternate approach
(Fig. 4f ). However, patients with a MELD score <10 had
significantly increased ORs of demonstrating a return to
their baseline MCS (correlated physical and mental
health factor model) score at the 24-week post-
treatment follow-up (OR 1.36 [95 % CI: 1.08, 1.70]).
Again, among the non-SVR group, patients who did
not achieve EVR (i.e. no viral response early or late) had
a statistically significant lower odds of a drop in MCS
(correlated factor model) score equal or greater than the
MIC between AVT initiation and end of AVT compared
with patients who achieved EVR (OR 0.76 [95 % CI:
0.58, 0.99]) (data not shown). Similarly, non-East Asians
were also less likely to report a meaningful drop in MCS
(correlated factor model) scores from AVT baseline to
the 24-week post treatment follow-up relative to whites/
other ethnicities (OR 0.54 [95 % CI: 0.38, 0.77]).
Results and model specifications in this article were
updated from those originally submitted as part of regu-
latory files in order to reflect the most recent and pre-
ferred analysis algorithm from the developers of the
original instruments, and further exploration and testing
of goodness-of-fit criteria and underlying model econo-
metric assumptions. Alternative models excluded spe-
cific clinical variables and/or interactions among clinical
variables as described earlier, or otherwise mathematic-
ally transformed predictor variables. Tests of these alter-
nate models did not result in fundamentally different
conclusions being reached regarding the predictive vari-
ables compared with analysis using original models.
Discussion
Analyses presented in this report indicate that the phys-
ical and mental functioning of the pooled sample from
the ENABLE studies were below that of the general US
population, although the differences were small (on the
order of <0.5 SD) in most cases. SF-36 scores from pre-
vious publications [5, 9, 10] generally agree with those in
this study, particularly regarding the impact upon spe-
cific SF-36v2 HRQoL domains. All patients enrolled in
the ENABLE trials had thrombocytopenia, and 90 % had
cirrhosis. Based on the similar safety and efficacy results
of the individual ENABLE trials, the descriptive HRQoL
analyses in the pooled sample is not expected to differ
from HRQoL results analyzed separately.
An important finding of this study is the observed de-
cline in HRQoL from baseline at AVT initiation and
during the course of treatment, with a return to baseline
levels upon completing treatment. Although declines in
HRQoL were smaller in eltrombopag-treated patients,
differences between this group and placebo-treated
patients were generally too small to be interpreted as
clinically meaningful when the change in HRQoL from
baseline to the end of treatment and from AVT baseline
to 24 weeks following the completion of AVT were
assessed. Treatment with eltrombopag did not mitigate
the effects of AVT on HRQoL or worsen adverse events
or symptoms of AVT versus placebo. The data suggest
that eltrombopag, by keeping platelet counts at levels
sufficient to initiate, continue, and complete INF-based
AVT, can provide patients who have severe liver disease
an opportunity to receive IFN-based treatment without
increasing adverse events such as flu-like symptoms or
depression that would further impact their HRQoL. Al-
though new non-IFN-based therapies are approved,
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these treatments may not be available to patients with
HCV in all geographical regions of the world, where IFN
may still be used to treat patients with HCV infection.
Regarding both EVR and SVR, analyses of HRQoL
changes showed a greater association and clearer patterns
in terms of smaller declines in mean HRQoL scores
among patients achieving a virologic response. Neverthe-
less, mean changes in patients achieving EVR and SVR
tended to be small compared with accepted thresholds of
minimally (clinically) important difference. Furthermore,
differences between patients achieving versus not achiev-
ing EVR were generally too small to be interpreted as
meaningful. Although differences in effect sizes were
slightly larger between patients who did and did not
achieve SVR, these were also too small to be interpreted
as meaningful. Achieving SVR and eliminating the viral
infection would be anticipated to slow the progression of
liver disease, but do not reverse it. Partitioning the
HRQoL effects into those related to INF-based therapy
versus those related to viral clearance (EVR and SVR),
IFN-based treatment would likely account for the majority
of the decline in HRQoL during treatment and improve-
ment in HRQoL after stopping treatment.
Patients infected with HCV genotypes 2 and 3 received
24 weeks of AVT versus 48 weeks for patients infected
with other genotypes. Nonetheless, with the exception of
the small interaction between SVR and EVR, none of the
5 clinical factors (SVR, EVR, genotype [2/3 vs. non-2/3],
treatment [eltrombopag or placebo], and cumulative IFN
dose) was confirmed as a predictor of meaningful
change in HRQoL. However, patients with a MELD
score <10 (those with less severe cirrhosis and liver dam-
age) were significantly more likely to return to their
overall baseline CLDQ-HCV, PCS, and MCS scores.
The logistic regression models revealed consistent OR
patterns for East Asians versus other Asians, and other
Asians versus white/other ethnicities for the CLDQ-HCV
and SF-36v2 PCS and MCS scores. East Asian patients
were consistently more likely to experience a meaningful
drop in HRQoL than white/other patients, but also more
likely to experience a return to their baseline scores. Other
Asians were generally less likely to experience a drop in
HRQoL versus white/other patients. Of note, Asian pa-
tients received a reduced eltrombopag dose, although
eltrombopag treatment seemed to have little impact on
HRQoL changes versus placebo. Assessments of HRQoL
in Asian patients with chronic HCV infections receiving
interferon-based AVT have not been reported in the lit-
erature. However, cultural differences in perceptions re-
garding health status may contribute to differences in
scores for the different scales of the SF-36v2, as was seen
in a study in Taiwan that revealed the vitality scale was a
stronger measure of mental health than physical health in
the local population [31].
The current study has limitations. Data were derived
from clinical trials, which may not fully reflect real-world
clinical practice. Relatively few patients achieved SVR or
EVR compared with those treated with AVT and random-
ized to receive eltrombopag; therefore, we may not have
been able to detect robust average change in HRQoL
because of the small number of responders. A general US
population was used as the norm in these analyses; how-
ever, the trials were international, and differences seen in
Asian patients enrolled in these studies may be affected by
this. Additionally, there are many options available for
measuring the MIC and no particular method is indicative
of or reliable in reflecting how patients themselves may
perceive change in their health status or quality of life.
The choice to use one half SD as an estimate of the MIC
was reasonable for expressing observed changes in a stan-
dardized way, but is also imperfect and may under- or
overestimate the true MIC, as discussed by Farivar [32] in
a critical review of Norman et al. [27].
Conclusions
A decline in HRQoL was observed during AVT with a
return to baseline levels at 24-week post treatment follow-
up. Treatment with eltrombopag neither significantly
reduced nor enhanced the pattern of changes in HRQoL
associated with AVT. Clinical factors did not appear to have
large effects on HRQoL, but East Asian patients were more
likely to experience declines in HRQoL during AVT.
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